Home : DrugWatch : Sensipar : Newsfeeds

Sensipar - Newsfeeds

NPS Pharmaceuticals Reports Third Quarter Results and Improved Cash ...
... principally due to (i) the shifting of certain expenses from 2009 to 2010, (ii) improvements in working capital, and (iii) higher-than-anticipated royalty revenue on REGPARA ® (cinacalcet HCl). The company’s reported cash burn and cash burn ...
Hot Off the Wire
NPS earns royalties on (i) Amgen's sales of Sensipar ® (cinacalcet HCl), (ii) Nycomed's sales of Preotact ® (parathyroid hormone 1-84 [rDNA origin] injection), (iii) Kyowa Kirin's sales of REGPARA ® (cinacalcet HCl), and (iv) Ortho-McNeil-Janssen ...
NPS Pharmaceuticals Reports Third Quarter Results and Improved Cash ...
NPS earns royalties on (i) Amgen's sales of Sensipar(R) (cinacalcet HCl), (ii) Nycomed's sales of Preotact(R) (parathyroid hormone 1-84 [rDNA origin] injection), (iii) Kyowa Kirin's sales of REGPARA(R) (cinacalcet HCl), and (iv) Ortho-McNeil-Janssen ...
Recent Comments
MRSA superbugs emerged independently in at least eight countries including the UK Methicillin-resistant Staphylococcus aureus (MRSA) bacteria that are increasingly resistant to vanco... Cinacalcet drug more successful than a placebo in treating ...
Amgen AB
Worldwide sales of Sensipar(R) (cinacalcet) increased 32 percent to $161 million in the third quarter of 2008 versus $122 million during the third quarter of 2007. This growth was principally driven by demand, primarily due to segment penetration. ...
Thirty-Seven Uninterrupted Years of Hemodialysis: A Case Report
These patients were all initiated on dialysis at a time when aluminum hydroxide (a cause of aluminum bone disease) was the preferred phosphate binder, before vitamin D analogs were in use, before cinacalcet was available, before the widespread use of ...
High-normal Phosphate Levels Linked To Early Atherosclerosis
Charles Herzog, MD, of USRDS and the Cardiovascular Special Studies Center, also in Minneapolis, MN, has received consulting fees as a member of the Executive Committee of the EVOLVE trial, an Amgen-sponsored clinical trial of Cinacalcet HCl Therapy ...
Brainstorm at Roche Leads to New Valium-Like Drugs (Update2)
``Sensipar does appear to be the validation of the concept because it's safe, has fewer side effects and represents a significant advance on whatever else is available,'' said Arthur Christopoulos, professor of pharmacology at Monash University in ...
Amgen Inc. Q4 2008 Earnings Call Transcript
Amgen Inc. (AMGN) Q4 2008 Earnings Call January 26, 2009 5:00 pm ET Executives Arvind Sood- Vice President of Investor ... Most Popular Searches in this transcript 1. aranesp 2. denosumab 3. nplate 4. enbrel 5. vectibix 6. biosimilar 7. 26 8. sensipar 9. thank ...
NPS Swings To Net Loss On Lower Revenue
Royalty revenue jumped 30.0% to $18.32 million, benefitting from higher royalties on Amgen's sales of Sensipar and Nycomed's sales of Preotact, as well as royalties of $0.70 million recognized on Kyowa Kirin's sales of Regpara. On the other hand ...
Wachovia Resumes Coverage on Amgen (AMGN) with an Outperform ...
"We based our Outperform rating for Amgen and our $61-65 valuation range on a forward 13-14x P/E to our 2011 EPS estimate of $5.65 non-GAAP, which assumes stabilization in core franchises and growth in the Sensipar and denosumab. Risks to the stock ...
Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 ...
Worldwide sales of Sensipar((R)) (cinacalcet) increased 11 percent to $167 million in the second quarter of 2009 versus $150 million during the second quarter of 2008, primarily as a result of increased demand. Vectibix((R)) (panitumumab) sales for ...
Highlights From AMGN's Q2 Conference Call: Positive on Glaxo (GSK ...
For Q2, worldwide Sensipar sales grew at 11% versus the second quarter of 2008, essentially due to demand. This performance reflects 11% growth in the U.S. and 13% growth internationally, which would be 27% excluding the negative impact of foreign ...
NPS Pharmaceuticals Reports Second Quarter 2009 Financial Results; Two ...
The company’s royalty rights related to Sensipar and Preotact currently secure non-recourse debt. At June 30, 2009, the outstanding principal balance on the non-recourse debt secured by the company’s Sensipar royalties was ...
Do you need a Sensipar attorney in Washington, DC? Contact one of our Sensipar attorneys in Washington, DC now.

Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.

Need A Sensipar Attorney?

First Name Last Name Email Address State
Has Your Health Been Negatively Affected?

Please Describe the Injury

Your Friend's Email Address

Your Email Address

Type a Message (optional)


Do you need a Sensipar attorney in Washington, DC? Contact one of our Sensipar attorneys in Washington, DC now.

 

Close (x)

Looking for an Attorney?


Please type your question:

Close (x)

logo Find Legal Help for Your Sensipar Case - Submit Your Information Below

Do you need legal assistance with your Sensipar case?
LegalView may be able to help.


Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *
Last name *
Email Address *
Phone Number *
()  -

State *
Legal Issue * DrugWatch: Sensipar Change
Was There an Injury?
Please Describe The Injury

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website [more...]

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.
This form is secure and encrypted. More information about secure forms and your privacy here.